Coding for High Risk Meds (eg, Plaquenil)

Slides:



Advertisements
Similar presentations
ADDICTION AND VISION LOSS
Advertisements

Billing & Documentation for Professional Charges for Clinical Trials.
Presenter: Juan Mo. Learning objectives What is gene therapy? What is a Dox-regulatable system and how can gene expression be regulated by Dox? What is.
Coding for Dry Eyes.
Innovative Color Vision Testing (simultaneous congenital & acquired)
Imaging Interpretation for the Comprehensive Eye Care Professional Blair Lonsberry, MS, OD, MEd., FAAO Diplomate, American Board of Optometry Clinic Director.
Clinical Guidance and Monitoring for Change Cecilia Fenerty MD FRCOphth.
2014 CODING UPDATE.
CNIB: SEEING BEYOND VISION LOSS
ELECTRO-OCULOGRAPHY Dr S R Pati.
SAMIR AL-MANSOURI, MD. e.g. - cataract - glaucoma - macular degeneration - diabetic retinopathy Chronic = slowly progressive visual loss Major causes:
Copyright restrictions may apply JAMA Ophthalmology Journal Club Slides: Chloroquine and Hydroxychloroquine Use Maculopathy Nika M, Blachley TS, Edwards.
Coding for Macular Degeneration 1. Office visit as above, 92 or 99 Frequency -As medically indicated (q 1mo, 3 mo, 6mo, 12mo) -No limit on office visits.
0 Glaucoma can take your sight away. Keep Vision in Your Future.
 SD OCT screens for retinopathy of prematurity in babies eyes  Uses narrow beams of light to penetrate deep layers of tissue and produce a 3-D image.
AMD & Treatment Options
Age related macular degeneration. Summary What is ARMD? How common is it? The symptoms Two types of ARMD –Dry –Wet Tests for ARMD Treatment and managing.
Diabetic Retinopathy Steven Sanislo, M.D. Assistant Professor Stanford University Department of Ophthalmology.
The Canadian Association of Optometrists
Coding for Diabetic Retinopathy 1. Office visit, 92 or 99 Frequency -As medically indicated (q 6mo, 12mo) -No limit on office visits -Manage separate.
1 Testing sensory visual function. 2 types: 1) psychophysical tests 2) electrophysical tests.
The Diabetic Retinopathy Clinical Research Network
Mobility Program Information on eye diseases and disorders was obtained at the St. Lukes Eye Clinic Website
Diabetes and the Eyes Kenyon Anderson, O.D.. Blindness Risk Diabetic eye disease, caused by diabetes, is a leading cause of blindness and vision loss.
LCD or Medical Policy 2 The rules by which a chart is judged during a Medicare audit 3.
C.A. Curcio, , ALARMGS Tutorial Clinico-pathologic Correlation: The Alabama Age-Related Maculopathy Grading System (ALARMGS) Christine A.Curcio,
Luu CD, Dimitrov PN, Robman L, et al. Role of flicker perimetry in predicting onset of late-stage age-related macular degeneration. Arch Ophthalmol. 2012;130(6):
RETINOPATHY OF PREMATURITY. What is Retinopathy of Prematurity (ROP)? b Disease of the retina in premature infants b Usually occurs in 1.5 kg or less.
Dr mahmood fauzi ASSIST PROF OPHTHALMOLOGY AL MAAREFA COLLEGE.
Visual Impairment. Factors Affecting Visual Function and Their Treatment Visual Acuity - ability to see "detail" –Measured using testing distance/letter.
Dr. Ayesha Abdullah Learning outcomes By the end of this lecture the students would be able to; Correlate the structural organization of the.
CIRRUS HD-OCT Version 7.6 CIRRUS HD-OCT Version 7.6 for Models 4000/400 Advancing Smart OCT CIR.7250.
The Diabetic Retinopathy Clinical Research Network Effect of Diabetes Education During Retinal Ophthalmology Visits on Diabetes Control (Protocol M) 11.
RELEVANCERELEVANCE Is the objective of the article on harm similar to your clinical dilemma? Yes, the article’s objective is similar to the clinical dilemma.
WHY CARE ABOUT YOUR EYES? Brought to you by the Centre for Healthy Aging at Providence and CNIB An Eye Health Information Session.
RETINOPATHY 2003 Clinical Practice Guidelines for the Prevention and Management of Diabetes in Canada.
Glaucoma Care Project Team Members: Geoffrey T. Emerick, M.D. Erin Herlihy, B.S. Marilyn Hauser, M.B.A. Dianna Greening, R.N. Walter M. Jay, M.D Opportunity.
Chronic Visual Loss. CHRONIC VISUAL LOSS 1. Measure intraocular pressure with a tonometer 2. Evaluate the nerve head 3. Evaluate the clarity of the lens.
Desinee Drakulich O.D.  I have no affiliation, nor do I received financial compensation from any of the companies or brands used in this presentation.
Glaucoma Madhav Vempali Vempali Medical Ltd. Glaucoma The healthy eye Light rays enter the eye through the cornea, pupil and lens. These light rays are.
Date of download: 5/30/2016 Copyright © 2016 American Medical Association. All rights reserved. From: An Unusual Retinal Phenotype Associated With a Novel.
Date of download: 6/1/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Gene Therapy for Leber Congenital Amaurosis Caused.
Primary Inflammatory Choriocapillaropathy Rupesh Agrawal, Carlos Pavesio Moorfields Eye Hospital, NHS Foundation Trust, London, United Kingdom.
Glaucoma Lily T. Im, MD. What is glaucoma?   Glaucoma is a group of diseases that damage the eye’s optic nerve and can result in vision loss and blindness.
Old Fibrotic Vascular tissue in End-Stage Proliferative Retinopathy
PREPARED BY: SUZAN BRUCE, CPC CLINICAL TRIALS OFFICE, UC DAVIS 1 Clinical Research Billing & Coding.
CERA Age-related macular degeneration- (AMD) information forum
Phacomorphic Glaucoma
Volume 123, Issue 6, Pages (June 2016)
Volume 123, Issue 3, Pages (March 2016)
Correlation between visual acuity
Mumbaieyecarecornealasik.com.
DIABETIC RETINOPATHY Süleyman ÖZEN.
From: Activated Retinal Pigment Epithelium, an Optical Coherence Tomography Biomarker for Progression in Age-Related Macular Degeneration Invest. Ophthalmol.
From: The Effects of Study Design and Spectrum Bias on the Evaluation of Diagnostic Accuracy of Confocal Scanning Laser Ophthalmoscopy in Glaucoma Invest.
Invest. Ophthalmol. Vis. Sci ;54(14):ORSF68-ORSF80. doi: /iovs
Glaucoma Clinical features and management
Dr William Wykes Southern General Hospital Glasgow
Vision and Vision Problems
Glaucoma: Changing Concepts and Future Directions
GH.NADERIAN, MD.
Multiple evanescent white dot syndrome
(case 6)  (A) Fundus photography showing subtle discrete areas of RPE atrophy (green areas). (case 6)  (A) Fundus photography showing subtle discrete areas.
Referral Refinement Event
Interreg-IPA Cross-border Cooperation Programme Romania-Serbia
Multiple Evanescent White Dot Syndrome (MEWDS)
Electrophysiologic Testing Index
Presentation transcript:

Coding for High Risk Meds (eg, Plaquenil)

Coding for High Risk Meds Office visit, 92 or 99 ICD examples: 362.55 Toxic maculopathy. Use E code of drug. 371.11 Anterior pigmentations 695.4 Lupus erythematosus 710.0 Systemic lupus erythematosus 714.0 Rheumatoid arthritis

Coding for High Risk Meds ICD examples: V58.69 Long term (current) use of other medications V58.83 Encounter for therapeutic drug monitoring V67.51 Following completed treatment with high-risk medication (After medication stopped, visits look for latent toxicity) V80.2 Special screening

Coding for High Risk Meds Office visit - Frequency -As medically indicated, dose-dependent. (q 3mo, 6mo, 12mo) -No limit on office visits. -Manage separate from routine vision care.

Coding for High Risk Meds 2011 Plaquenil Screening Tests (Am.Acad.Ophthal.) Extended Ophthalmoscopy Fundus Photography Visual Field Scanning Imaging, FAF, or mfERG

Coding for High Risk Meds Extended Ophthalmoscopy -Should not be used as screening test alone, due to low sensitivity. (AAO)  

Coding for High Risk Meds Extended Ophthalmoscopy -362.55 Toxic maculopathy, often paid. Use E code for drug.

Coding for High Risk Meds Fundus Photography -Not sensitive enough to identify early findings associated with retinal toxicity. (AAO)

Coding for High Risk Meds Fundus Photography - ICD examples 362.55 Toxic maculopathy. Use E code for drug 710.0 Systemic lupus erythematosus V58.69 Long term (current) use of other medications  

Coding for High Risk Meds Visual Field - 10-2 -Loss in paracentral retina may be 1st sign of toxicity. (AAO) -Paracentral defects indicate abnormality before RPE changes visible. (AAO)  

Coding for High Risk Meds Visual Field – ICD examples often paid 362.55 Toxic maculopathy. Use E code for drug 371.11 Anterior pigmentation V58.69 Long term (current) use of other medications V58.83 Encounter for therapeutic drug monitoring; V58.69 Long term (current) use of other  

Coding for High Risk Meds Scanning Imaging, FAF, or mfERG Testing should include at least one of these 3.  (AAO)

Coding for High Risk Meds 1) SD-OCT 92134 (retina) Early change may reflect macular thinning, disruption at photoreception integrity line or inner/outer segment layer. (AAO) ICD, often paid 362.55 Toxic maculopathy. Use E code for drug.  

Coding for High Risk Meds 1) SD-OCT 92134 (retina)   A baseline study of optic nerve and retinal imaging is considered medically necessary before initiation of chloroquine, hydroxychloroquine. Aetna Clinical Policy

Coding for High Risk Meds 1) SD-OCT 92134 (retina) Nine Medicare Part B contractors: 6 approve V58.69 (Novitas, CGS, First Coast, NGS, NHIC, WPS). Three contractors (Cahaba, Noridan, Palmetto) are silent about V58.69 – no LCD for OCT.

Coding for High Risk Meds 1) SD-OCT 92134 (retina) States with Cahaba, Noridan, Palmetto: If 92134 with V58.69 is denied (as in past), submit appeal, giving evidence that Novitas, CGS, First Coast, NGS, NHIC, WPS pay for V58.69. Chances are good the contractor will reverse its decision and it will be paid.

Coding for High Risk Meds 2) FAF: 92134 (retina) or 92250 “Fundus AutoFluorescence” -Early RPE defect damage shows reduction of autofluorescence. (AAO) -Photoreceptor damage shows increase of autofluorescence. (AAO) ICD, may be paid 362.55 Toxic maculopathy. Use E code for drug  

Coding for High Risk Meds 3) mfERG Multi-Focal Electroretinography, 92275. Objectively documents paracentral functional damage. (AAO) ICD, may be paid 362.55 Toxic maculopathy. Use E code for drug  

Coding for High Risk Meds Secondary ICD Code, ie, “E” Code Example: E931.4 Antimalarials and drugs acting on other blood protozoa  

Thank You! Evaluations Questions You Made It! Thank You! Evaluations Questions